Emergent BioSolutions (EBS) Notes Payables (2016 - 2024)

Emergent BioSolutions' Notes Payables history runs 8 years deep, the most recent figure standing at $800000.0 for Q3 2024.

• In Q3 2024, Notes Payables fell 99.81% year-over-year to $800000.0; the TTM figure through Sep 2024 stood at $800000.0 (down 99.81% YoY), while the FY2023 annual figure was $413.7 million, down 56.78% from the prior year.
• Notes Payables was $800000.0 for Q3 2024 at Emergent BioSolutions, down from $415.2 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $957.3 million in Q4 2022 to a low of $800000.0 in Q3 2024.
• Historically, Notes Payables has averaged $231.0 million across 5 years, with a median of $31.6 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Notes Payables soared 2929.43% in 2022, then slumped 99.81% in 2024.
• A 5-year view of Notes Payables shows it stood at $33.8 million in 2020, then dropped by 6.51% to $31.6 million in 2021, then jumped by 2929.43% to $957.3 million in 2022, then plunged by 56.78% to $413.7 million in 2023, then sank by 99.81% to $800000.0 in 2024.
• The last three Notes Payables figures came in at $800000.0 (Q3 2024), $415.2 million (Q2 2024), and $459.2 million (Q1 2024), per Business Quant data.